Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Diabetic Macular Oedema
Interventions
DRUG

Triamcinolone acetate

When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.

Trial Locations (1)

2000

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney

All Listed Sponsors
lead

University of Sydney

OTHER

NCT00148330 - Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study | Biotech Hunter | Biotech Hunter